These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 36006993)

  • 1. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
    Zhang H; Hu B; Lv P; Liu Y; Guo M; Wu Z; Zhou K; Dai M; Yu X; Liu Z; Yu B; Xu L; Guo M; Cai K; Li Y
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering ACE2 decoy receptors to combat viral escapability.
    Arimori T; Ikemura N; Okamoto T; Takagi J; Standley DM; Hoshino A
    Trends Pharmacol Sci; 2022 Oct; 43(10):838-851. PubMed ID: 35902282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes.
    Guo H; Hu BJ; Yang XL; Zeng LP; Li B; Ouyang S; Shi ZL
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32699095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Skeeters SS; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    EMBO Mol Med; 2022 Nov; 14(11):e16109. PubMed ID: 36094679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019.
    Feng L; Fu S; Zhang P; Zhang Y; Zhao Y; Yao Y; Luo L; Ping P
    Front Public Health; 2022; 10():1050034. PubMed ID: 36518573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain.
    Pitsillou E; Liang JJ; Beh RC; Hung A; Karagiannis TC
    Comput Biol Med; 2022 Oct; 149():106035. PubMed ID: 36055162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
    Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
    mBio; 2024 Aug; 15(8):e0090724. PubMed ID: 38953636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH
    Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs.
    Kazemi S; López-Muñoz AD; Hollý J; Jin L; Yewdell JW; Dolan BP
    J Virol; 2022 Sep; 96(17):e0025622. PubMed ID: 36000847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
    Miller A; Leach A; Thomas J; McAndrew C; Bentley E; Mattiuzzo G; John L; Mirazimi A; Harris G; Gamage N; Carr S; Ali H; Van Montfort R; Rabbitts T
    Sci Rep; 2021 May; 11(1):10617. PubMed ID: 34012108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2.
    Gong SY; Ding S; Benlarbi M; Chen Y; Vézina D; Marchitto L; Beaudoin-Bussières G; Goyette G; Bourassa C; Bo Y; Medjahed H; Levade I; Pazgier M; Côté M; Richard J; Prévost J; Finzi A
    Viruses; 2022 Sep; 14(10):. PubMed ID: 36298733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    Kumar S; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.